Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис:
http://hdl.handle.net/20.500.12188/7319| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Crvenkova, Simonida | en_US |
| dc.contributor.author | Ivkovski, Lj | en_US |
| dc.contributor.author | Dimovski, A | en_US |
| dc.contributor.author | Kaeva, B | en_US |
| dc.date.accessioned | 2020-03-17T14:03:07Z | - |
| dc.date.available | 2020-03-17T14:03:07Z | - |
| dc.date.issued | 2012 | - |
| dc.identifier.issn | 0351-3254 | - |
| dc.identifier.uri | http://hdl.handle.net/20.500.12188/7319 | - |
| dc.description.abstract | The aim of this study was to evaluate tumour response, QoL and adverse effects of erlotinib, EGFR tyrosine kinase inhibitor (TKI), as a second line therapy for patients with EGFR mutation in NSCLC, after failure of previous first-line therapy. | en_US |
| dc.language.iso | en | en_US |
| dc.relation.ispartof | Prilozi | en_US |
| dc.title | Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience | en_US |
| dc.identifier.volume | 33 | - |
| dc.identifier.issue | 1 | - |
| item.grantfulltext | none | - |
| item.fulltext | No Fulltext | - |
| crisitem.author.dept | Faculty of Medicine | - |
| Appears in Collections: | Faculty of Medicine: Journal Articles | |
Записите во DSpace се заштитени со авторски права, со сите права задржани, освен ако не е поинаку наведено.